{"id":880763,"date":"2025-09-02T08:28:07","date_gmt":"2025-09-02T12:28:07","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/calcimedica-to-participate-in-the-h-c-wainwright-27th-annual-global-investment-conference\/"},"modified":"2025-09-02T08:28:07","modified_gmt":"2025-09-02T12:28:07","slug":"calcimedica-to-participate-in-the-h-c-wainwright-27th-annual-global-investment-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/calcimedica-to-participate-in-the-h-c-wainwright-27th-annual-global-investment-conference\/","title":{"rendered":"CalciMedica to Participate in the H.C. Wainwright 27th Annual Global Investment Conference"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"legendSpanClass\"><br \/>\n          <span class=\"xn-location\">LA JOLLA, Calif.<\/span><br \/>\n        <\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">Sept. 2, 2025<\/span><\/span> \/PRNewswire\/ &#8212; CalciMedica Inc. (&#8220;CalciMedica&#8221; or the &#8220;Company&#8221;) (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced that <span class=\"xn-person\">Rachel Leheny<\/span>, Ph.D., Chief Executive Officer, will present at the H.C. Wainwright 27th Annual Global Investment Conference on <span class=\"xn-chron\">Monday, September 8, 2025<\/span>, at <span class=\"xn-chron\">3:30 p.m. ET<\/span>.<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<p>\n          <a href=\"https:\/\/mma.prnewswire.com\/media\/685404\/calcimedica_v3.html\" target=\"_blank\" rel=\"nofollow\"><br \/>\n            <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/685404\/calcimedica_v3.jpg\" title=\"CalciMedica Logo (PRNewsfoto\/CalciMedica, Inc.)\" alt=\"CalciMedica Logo (PRNewsfoto\/CalciMedica, Inc.)\" \/><br \/>\n          <\/a>\n        <\/p>\n<\/p><\/div>\n<p>A live webcast of the presentation can be accessed in the &#8220;<a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4498549-1&amp;h=1305815305&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4463358-1%26h%3D4069194318%26u%3Dhttps%253A%252F%252Fir.calcimedica.com%252Fnews-events%252Fevents-presentations%26a%3DIR%2BEvents%2Band%2BPresentations&amp;a=IR+Events+and+Presentations\" target=\"_blank\" rel=\"nofollow\">IR Events and Presentations<\/a>&#8221; section of\u00a0CalciMedica&#8217;s\u00a0IR website.\u00a0A replay of the webcast will be archived on the Company&#8217;s website for 90 days.<\/p>\n<p>\n        <b>About CalciMedica<br \/><\/b>CalciMedica\u00a0is a clinical-stage biopharmaceutical company focused on developing novel CRAC channel inhibition therapies for inflammatory and immunologic diseases.\u00a0CalciMedica&#8217;s\u00a0proprietary technology targets the inhibition of CRAC channels to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory and immunologic diseases for which there are currently no approved therapies.\u00a0CalciMedica&#8217;s\u00a0lead product candidate\u00a0Auxora\u2122 has demonstrated positive and consistent clinical results in multiple completed efficacy clinical trials and been well-tolerated in over 350 critically ill patients dosed.\u00a0CalciMedica\u00a0has announced data for a Phase <span class=\"xn-money\">2b<\/span> trial (called CARPO \u2013\u00a0<a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4498549-1&amp;h=2835196358&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4463358-1%26h%3D1249673562%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D4447318-1%2526h%253D2628687410%2526u%253Dhttps%25253A%25252F%25252Fc212.net%25252Fc%25252Flink%25252F%25253Ft%25253D0%252526l%25253Den%252526o%25253D4365141-1%252526h%25253D2227956491%252526u%25253Dhttps%2525253A%2525252F%2525252Fc212.net%2525252Fc%2525252Flink%2525252F%2525253Ft%2525253D0%25252526l%2525253Den%25252526o%2525253D4354022-1%25252526h%2525253D507515521%25252526u%2525253Dhttps%252525253A%252525252F%252525252Fc212.net%252525252Fc%252525252Flink%252525252F%252525253Ft%252525253D0%2525252526l%252525253Den%2525252526o%252525253D4339678-1%2525252526h%252525253D2357721873%2525252526u%252525253Dhttps%25252525253A%25252525252F%25252525252Fc212.net%25252525252Fc%25252525252Flink%25252525252F%25252525253Ft%25252525253D0%252525252526l%25252525253Den%252525252526o%25252525253D4243427-1%252525252526h%25252525253D2669185696%252525252526u%25252525253Dhttps%2525252525253A%2525252525252F%2525252525252Fc212.net%2525252525252Fc%2525252525252Flink%2525252525252F%2525252525253Ft%2525252525253D0%25252525252526l%2525252525253Den%25252525252526o%2525252525253D4231092-1%25252525252526h%2525252525253D1699697110%25252525252526u%2525252525253Dhttps%252525252525253A%252525252525252F%252525252525252Fclinicaltrials.gov%252525252525252Fstudy%252525252525252FNCT04681066%252525252525253Fterm%252525252525253DNCT04681066%2525252525252526rank%252525252525253D1%25252525252526a%2525252525253DNCT04681066%252525252526a%25252525253DNCT04681066%2525252526a%252525253DNCT04681066%25252526a%2525253DNCT04681066%252526a%25253DNCT04681066%2526a%253DNCT04681066%26a%3DNCT04681066&amp;a=NCT04681066\" target=\"_blank\" rel=\"nofollow\">NCT04681066<\/a>) in patients with acute pancreatitis (AP) and accompanying systemic inflammatory response syndrome (SIRS) and for a Phase 2 trial (called CARDEA \u2013<a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4498549-1&amp;h=2024007408&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4463358-1%26h%3D2204292654%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D4447318-1%2526h%253D374099527%2526u%253Dhttps%25253A%25252F%25252Fc212.net%25252Fc%25252Flink%25252F%25253Ft%25253D0%252526l%25253Den%252526o%25253D4365141-1%252526h%25253D2057969415%252526u%25253Dhttps%2525253A%2525252F%2525252Fc212.net%2525252Fc%2525252Flink%2525252F%2525253Ft%2525253D0%25252526l%2525253Den%25252526o%2525253D4354022-1%25252526h%2525253D1581608759%25252526u%2525253Dhttps%252525253A%252525252F%252525252Fc212.net%252525252Fc%252525252Flink%252525252F%252525253Ft%252525253D0%2525252526l%252525253Den%2525252526o%252525253D4339678-1%2525252526h%252525253D2705666193%2525252526u%252525253Dhttps%25252525253A%25252525252F%25252525252Fc212.net%25252525252Fc%25252525252Flink%25252525252F%25252525253Ft%25252525253D0%252525252526l%25252525253Den%252525252526o%25252525253D4243427-1%252525252526h%25252525253D3152801644%252525252526u%25252525253Dhttps%2525252525253A%2525252525252F%2525252525252Fc212.net%2525252525252Fc%2525252525252Flink%2525252525252F%2525252525253Ft%2525252525253D0%25252525252526l%2525252525253Den%25252525252526o%2525252525253D4231092-1%25252525252526h%2525252525253D1827566996%25252525252526u%2525252525253Dhttps%252525252525253A%252525252525252F%252525252525252Fc212.net%252525252525252Fc%252525252525252Flink%252525252525252F%252525252525253Ft%252525252525253D0%2525252525252526l%252525252525253Den%2525252525252526o%252525252525253D4206849-1%2525252525252526h%252525252525253D575802973%2525252525252526u%252525252525253Dhttps%25252525252525253A%25252525252525252F%25252525252525252Fclinicaltrials.gov%25252525252525252Fstudy%25252525252525252FNCT04345614%2525252525252526a%252525252525253DNCT04345614%25252525252526a%2525252525253DNCT04345614%252525252526a%25252525253DNCT04345614%2525252526a%252525253DNCT04345614%25252526a%2525253DNCT04345614%252526a%25253DNCT04345614%2526a%253DNCT04345614%26a%3DNCT04345614&amp;a=NCT04345614\" target=\"_blank\" rel=\"nofollow\">NCT04345614<\/a>) in patients with COVID pneumonia. The Company is currently conducting a Phase 2 trial (called KOURAGE \u2013<a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4498549-1&amp;h=429136588&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4463358-1%26h%3D2496800989%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D4447318-1%2526h%253D1993166025%2526u%253Dhttps%25253A%25252F%25252Fc212.net%25252Fc%25252Flink%25252F%25253Ft%25253D0%252526l%25253Den%252526o%25253D4365141-1%252526h%25253D3565668751%252526u%25253Dhttps%2525253A%2525252F%2525252Fc212.net%2525252Fc%2525252Flink%2525252F%2525253Ft%2525253D0%25252526l%2525253Den%25252526o%2525253D4354022-1%25252526h%2525253D1219378198%25252526u%2525253Dhttps%252525253A%252525252F%252525252Fc212.net%252525252Fc%252525252Flink%252525252F%252525253Ft%252525253D0%2525252526l%252525253Den%2525252526o%252525253D4339678-1%2525252526h%252525253D3911003323%2525252526u%252525253Dhttps%25252525253A%25252525252F%25252525252Fc212.net%25252525252Fc%25252525252Flink%25252525252F%25252525253Ft%25252525253D0%252525252526l%25252525253Den%252525252526o%25252525253D4243427-1%252525252526h%25252525253D2144183414%252525252526u%25252525253Dhttps%2525252525253A%2525252525252F%2525252525252Fc212.net%2525252525252Fc%2525252525252Flink%2525252525252F%2525252525253Ft%2525252525253D0%25252525252526l%2525252525253Den%25252525252526o%2525252525253D4231092-1%25252525252526h%2525252525253D78069076%25252525252526u%2525252525253Dhttps%252525252525253A%252525252525252F%252525252525252Fclinicaltrials.gov%252525252525252Fstudy%252525252525252FNCT06374797%252525252525253Fterm%252525252525253DKOURAGE%2525252525252526rank%252525252525253D1%25252525252526a%2525252525253DNCT06374797%252525252526a%25252525253DNCT06374797%2525252526a%252525253DNCT06374797%25252526a%2525253DNCT06374797%252526a%25253DNCT06374797%2526a%253DNCT06374797%26a%3DNCT06374797&amp;a=NCT06374797\" target=\"_blank\" rel=\"nofollow\">NCT06374797<\/a>) in patients with acute kidney injury (AKI) with associated respiratory failure. For more information, please visit <a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4498549-1&amp;h=1396099454&amp;u=http%3A%2F%2Fwww.calcimedica.com%2F&amp;a=www.calcimedica.com\" target=\"_blank\" rel=\"nofollow\">www.calcimedica.com<\/a>.<\/p>\n<p>\n        <b>Contact Information<br \/><\/b><br \/>\n        <span class=\"xn-person\">Kevin Murphy<\/span><br \/>\n        <br \/>\n        <u><br \/>\n          <a href=\"mailto:calcimedica@argotpartners.com\" target=\"_blank\" rel=\"nofollow\">calcimedica@argotpartners.com<\/a><br \/>\n          <br \/>\n        <\/u>(212) 600-1902<\/p>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=LA62127&amp;sd=2025-09-02\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"https:\/\/www.prnewswire.com\/news-releases\/calcimedica-to-participate-in-the-hc-wainwright-27th-annual-global-investment-conference-302542326.html\" target=\"_blank\">https:\/\/www.prnewswire.com\/news-releases\/calcimedica-to-participate-in-the-hc-wainwright-27th-annual-global-investment-conference-302542326.html<\/a><\/p>\n<p>SOURCE  CalciMedica, Inc.<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=LA62127&amp;Transmission_Id=202509020700PR_NEWS_USPR_____LA62127&amp;DateId=20250902\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire LA JOLLA, Calif. , Sept. 2, 2025 \/PRNewswire\/ &#8212; CalciMedica Inc. (&#8220;CalciMedica&#8221; or the &#8220;Company&#8221;) (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced that Rachel Leheny, Ph.D., Chief Executive Officer, will present at the H.C. Wainwright 27th Annual Global Investment Conference on Monday, September 8, 2025, at 3:30 p.m. ET. A live webcast of the presentation can be accessed in the &#8220;IR Events and Presentations&#8221; section of\u00a0CalciMedica&#8217;s\u00a0IR website.\u00a0A replay of the webcast will be archived on the Company&#8217;s website for 90 days. About CalciMedicaCalciMedica\u00a0is a clinical-stage biopharmaceutical company focused on developing novel CRAC channel inhibition therapies for inflammatory and &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/calcimedica-to-participate-in-the-h-c-wainwright-27th-annual-global-investment-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;CalciMedica to Participate in the H.C. Wainwright 27th Annual Global Investment Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-880763","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>CalciMedica to Participate in the H.C. Wainwright 27th Annual Global Investment Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/calcimedica-to-participate-in-the-h-c-wainwright-27th-annual-global-investment-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CalciMedica to Participate in the H.C. Wainwright 27th Annual Global Investment Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire LA JOLLA, Calif. , Sept. 2, 2025 \/PRNewswire\/ &#8212; CalciMedica Inc. (&#8220;CalciMedica&#8221; or the &#8220;Company&#8221;) (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced that Rachel Leheny, Ph.D., Chief Executive Officer, will present at the H.C. Wainwright 27th Annual Global Investment Conference on Monday, September 8, 2025, at 3:30 p.m. ET. A live webcast of the presentation can be accessed in the &#8220;IR Events and Presentations&#8221; section of\u00a0CalciMedica&#8217;s\u00a0IR website.\u00a0A replay of the webcast will be archived on the Company&#8217;s website for 90 days. About CalciMedicaCalciMedica\u00a0is a clinical-stage biopharmaceutical company focused on developing novel CRAC channel inhibition therapies for inflammatory and &hellip; Continue reading &quot;CalciMedica to Participate in the H.C. Wainwright 27th Annual Global Investment Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/calcimedica-to-participate-in-the-h-c-wainwright-27th-annual-global-investment-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-02T12:28:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/685404\/calcimedica_v3.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/calcimedica-to-participate-in-the-h-c-wainwright-27th-annual-global-investment-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/calcimedica-to-participate-in-the-h-c-wainwright-27th-annual-global-investment-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"CalciMedica to Participate in the H.C. Wainwright 27th Annual Global Investment Conference\",\"datePublished\":\"2025-09-02T12:28:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/calcimedica-to-participate-in-the-h-c-wainwright-27th-annual-global-investment-conference\\\/\"},\"wordCount\":301,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/calcimedica-to-participate-in-the-h-c-wainwright-27th-annual-global-investment-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/685404\\\/calcimedica_v3.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/calcimedica-to-participate-in-the-h-c-wainwright-27th-annual-global-investment-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/calcimedica-to-participate-in-the-h-c-wainwright-27th-annual-global-investment-conference\\\/\",\"name\":\"CalciMedica to Participate in the H.C. Wainwright 27th Annual Global Investment Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/calcimedica-to-participate-in-the-h-c-wainwright-27th-annual-global-investment-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/calcimedica-to-participate-in-the-h-c-wainwright-27th-annual-global-investment-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/685404\\\/calcimedica_v3.jpg\",\"datePublished\":\"2025-09-02T12:28:07+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/calcimedica-to-participate-in-the-h-c-wainwright-27th-annual-global-investment-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/calcimedica-to-participate-in-the-h-c-wainwright-27th-annual-global-investment-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/calcimedica-to-participate-in-the-h-c-wainwright-27th-annual-global-investment-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/685404\\\/calcimedica_v3.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/685404\\\/calcimedica_v3.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/calcimedica-to-participate-in-the-h-c-wainwright-27th-annual-global-investment-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CalciMedica to Participate in the H.C. Wainwright 27th Annual Global Investment Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CalciMedica to Participate in the H.C. Wainwright 27th Annual Global Investment Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/calcimedica-to-participate-in-the-h-c-wainwright-27th-annual-global-investment-conference\/","og_locale":"en_US","og_type":"article","og_title":"CalciMedica to Participate in the H.C. Wainwright 27th Annual Global Investment Conference - Market Newsdesk","og_description":"PR Newswire LA JOLLA, Calif. , Sept. 2, 2025 \/PRNewswire\/ &#8212; CalciMedica Inc. (&#8220;CalciMedica&#8221; or the &#8220;Company&#8221;) (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced that Rachel Leheny, Ph.D., Chief Executive Officer, will present at the H.C. Wainwright 27th Annual Global Investment Conference on Monday, September 8, 2025, at 3:30 p.m. ET. A live webcast of the presentation can be accessed in the &#8220;IR Events and Presentations&#8221; section of\u00a0CalciMedica&#8217;s\u00a0IR website.\u00a0A replay of the webcast will be archived on the Company&#8217;s website for 90 days. About CalciMedicaCalciMedica\u00a0is a clinical-stage biopharmaceutical company focused on developing novel CRAC channel inhibition therapies for inflammatory and &hellip; Continue reading \"CalciMedica to Participate in the H.C. Wainwright 27th Annual Global Investment Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/calcimedica-to-participate-in-the-h-c-wainwright-27th-annual-global-investment-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2025-09-02T12:28:07+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/685404\/calcimedica_v3.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/calcimedica-to-participate-in-the-h-c-wainwright-27th-annual-global-investment-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/calcimedica-to-participate-in-the-h-c-wainwright-27th-annual-global-investment-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"CalciMedica to Participate in the H.C. Wainwright 27th Annual Global Investment Conference","datePublished":"2025-09-02T12:28:07+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/calcimedica-to-participate-in-the-h-c-wainwright-27th-annual-global-investment-conference\/"},"wordCount":301,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/calcimedica-to-participate-in-the-h-c-wainwright-27th-annual-global-investment-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/685404\/calcimedica_v3.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/calcimedica-to-participate-in-the-h-c-wainwright-27th-annual-global-investment-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/calcimedica-to-participate-in-the-h-c-wainwright-27th-annual-global-investment-conference\/","name":"CalciMedica to Participate in the H.C. Wainwright 27th Annual Global Investment Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/calcimedica-to-participate-in-the-h-c-wainwright-27th-annual-global-investment-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/calcimedica-to-participate-in-the-h-c-wainwright-27th-annual-global-investment-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/685404\/calcimedica_v3.jpg","datePublished":"2025-09-02T12:28:07+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/calcimedica-to-participate-in-the-h-c-wainwright-27th-annual-global-investment-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/calcimedica-to-participate-in-the-h-c-wainwright-27th-annual-global-investment-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/calcimedica-to-participate-in-the-h-c-wainwright-27th-annual-global-investment-conference\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/685404\/calcimedica_v3.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/685404\/calcimedica_v3.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/calcimedica-to-participate-in-the-h-c-wainwright-27th-annual-global-investment-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"CalciMedica to Participate in the H.C. Wainwright 27th Annual Global Investment Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/880763","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=880763"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/880763\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=880763"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=880763"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=880763"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}